Italy Insulin Drugs and Delivery Devices Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 531.86 Million |
| Market Size (2029) | USD 572.96 Million |
| CAGR (2024 - 2029) | 1.50 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Italy Insulin Drugs and Delivery Devices Market Analysis
The Italy Insulin Drugs And Delivery Devices Market size is estimated at USD 531.86 million in 2024, and is expected to reach USD 572.96 million by 2029, growing at a CAGR of 1.5% during the forecast period (2024-2029).
The insulin drugs and delivery devices market in Italy is experiencing significant growth, driven by the rising prevalence of diabetes and advancements in technology. According to the International Diabetes Federation (IDF), Italy's diabetic population is expected to increase from 4,470.3 thousand in 2021 to around 4,699.1 thousand by 2030.
Italy's National Healthcare Service (NHS) stands out for its commitment to universal healthcare, ensuring that citizens, especially those with diabetes (PwD), have unfettered access to essential medicines, devices, and medical services, all without incurring any out-of-pocket expenses. This robust system is further bolstered by the presence of numerous diabetes centers across the country, offering free treatment at the point of delivery.
The insulin devices market in Italy is witnessing a surge in technological advancements. These innovations have not only introduced more comfortable devices for patients but have also paved the way for new, more patient-friendly options. For instance, in March 2024, at the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, Insulet Corporation showcased promising results from a clinical trial comparing its Omnipod 5 to non-automated insulin therapy. The study revealed that Omnipod 5 users experienced a 17.5% improvement in their time in the target glucose range, along with reduced HbA1c levels and less time spent in hypoglycemia. Notably, individuals with initially higher HbA1c levels also saw a decrease in their mean glucose levels, further underscoring the benefits of these advanced products in the Italian market.
Italy's insulin drugs and delivery devices market is poised for continued growth, driven by increasing diabetes prevalence and significant technological advancements. The commitment of the Italian National Healthcare Service to provide comprehensive care for people with diabetes further supports market expansion.
Italy Insulin Drugs and Delivery Devices Market Trends
Strategic Initiatives by the Government and Organizations are Growing
Increasing initiatives by the government and non-profit organizations to enhance the awareness and treatment accessibility of diabetes in the country are likely to boost market growth. For instance, the National Diabetes Plan is a guideline proposed by the government, emphasizing patient-centric care and setting the agenda and standards for diabetes care. However, its execution varies widely across the country's 20 regions, falling under the purview of local and regional authorities.
Under the National Diabetes Plan, type 1 diabetes patients receive essential diabetic supplies, such as insulin, at no cost. Patients are also required to visit an endocrinologist or general practitioner every 3-4 months. Additionally, clinics must provide specialized services, including nurses, dieticians, and psychologists.
Companies' strategic initiatives, such as regional expansions and innovative product launches, are set to propel the market’s growth. For instance, in November 2023, ViCentra, in partnership with Dexcom G6, introduced a cutting-edge hybrid closed-loop insulin system. ViCentra is expected to launch this innovative system in 2024, strategically emphasizing the Italian market. The resulting system functions as an artificial pancreas by merging ViCentra's Diabeloop DBLG1 algorithm with Dexcom's G6 monitor. Noteworthy features include self-learning abilities and a heightened focus on user convenience.
The combined efforts of government initiatives and corporate innovations are significantly enhancing diabetes care in Italy. This synergy is expected to drive market growth in the coming years.
The Insulin Pumps Segment is Expected to Witness Significant Growth Over the Forecast Period
The insulin pump market is poised to record significant growth during the forecast period.
An insulin pump administers insulin continuously or on demand. It serves as an alternative to daily injections or insulin pens. This method, known as insulin pump therapy, is widely accepted for managing type 1 diabetes (T1DM). These pumps offer near-physiological insulin delivery, compensating for the pancreas's inability to produce insulin. Some models even feature remote controls, allowing parents to manage insulin dosages from a distance, a boon when children are busy playing or eating. Compared to injections, insulin pumps lead to fewer blood glucose swings, less discomfort, and more precise dosing, underscoring their market appeal.
Recognizing these benefits, companies are integrating AI technology into insulin pumps, enhancing user-friendliness and promoting insulin usage. For instance, Medtronic Italia's Minimed Mobile App syncs an insulin pump with the user's smartphone, offering real-time pump data. The mobile application allows users to transfer and manage their pump data seamlessly.
Market players are bolstering their presence through innovative product launches. In August 2022, A. Menarini Diagnostics introduced GlucoMen Day PUMP in Europe—a tubeless, wearable, and disposable insulin pump. By 2023, the product had debuted in 17 countries, with an initial rollout in 10 countries, including Italy, in 2022.
The insulin pump market is on an upward growth trajectory that can be attributed to technological advancements and strategic product launches. These developments promise to enhance diabetes management and improve the quality of life for individuals with T1DM.
Italy Insulin Drugs and Delivery Devices Industry Overview
Italy's insulin drugs and delivery devices market is consolidated, with a few significant and generic players, including Medtronic, Sanofi, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Novo Nordisk A/S. Companies use mergers and acquisitions to their market presence. Eli Lilly and Boehringer Ingelheim have an alliance to develop and commercialize Basaglar (Insulin Glargine).
Italy Insulin Drugs and Delivery Devices Market Leaders
-
Medtronics
-
Sanofi
-
F. Hoffmann-La Roche Ltd
-
Eli Lilly and Company
-
Becton, Dickinson and Company
*Disclaimer: Major Players sorted in no particular order
Italy Insulin Drugs and Delivery Devices Market News
- March 2024: Medical Technology and Devices, with production facilities in Italy and Poland, acquired Ypsomed's operations for insulin pen needles and blood sugar monitoring.
- March 2024: Medtronic PLC presented new clinical and real-world data for its MiniMed 780G system. This data encompassed a global perspective, incorporating feedback from early adopters in both the United States and Italy. The company chose the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Italy as the platform to unveil these findings.
Italy Insulin Drugs And Delivery Devices Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Strategic Initiatives By The Government and Organizations
4.2.2 Increasing Prevalence Of Diabetes In Italy
4.3 Market Restraints
4.3.1 Limited Availability of Affordable Drug Delivery Devices In The Country
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size By Value - USD)
5.1 By Drug
5.1.1 Basal Or Long-Acting Insulins
5.1.1.1 Lantus (Insulin Glargine)
5.1.1.2 Levemir (Insulin Detemir)
5.1.1.3 Toujeo (Insulin Glargine)
5.1.1.4 Others
5.1.2 Bolus Or Fast-Acting Insulins
5.1.2.1 NovoRapid/Novolog (Insulin Aspart)
5.1.2.2 Humalog (Insulin Lispro)
5.1.2.3 Apidra (Insulin Glulisine)
5.1.2.4 Others
5.1.3 Traditional Human Insulins
5.1.3.1 Novolin/Mixtard/Actrapid/Insulatard
5.1.3.2 Humulin
5.1.3.3 Insuman
5.1.4 Others
5.2 By Device
5.2.1 Insulin Pumps
5.2.2 Insulin Pens
5.2.3 Insulin Syringes
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population (2021-2029)
6.2 Type-2 Diabetes Population (2021-2029)
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk A/S
7.1.2 Sanofi
7.1.3 Eli Lilly and Company
7.1.4 Biocon Biologics Ltd
7.1.5 Medtronic
7.1.6 Becton, Dickinson And Company
- *List Not Exhaustive
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Italy Insulin Drugs and Delivery Devices Industry Segmentation
Insulin is administered to regulate blood sugar levels in individuals diagnosed with type 1 diabetes, a condition characterized by the body's inability to produce insulin and consequently unable to regulate blood sugar levels. It is also prescribed for individuals with type 2 diabetes, a condition where blood sugar levels are elevated due to the body's inadequate production or utilization of insulin, and oral medications alone are insufficient in managing the condition. There are several ways to give insulin subcutaneously, including a vial and syringe, an insulin pen, and continuous subcutaneous insulin infusion (CSII).
Italy's insulin drugs and delivery devices market is segmented by drugs and devices. By drugs, the market is segmented into basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, and others. By devices, the market is segmented into insulin pens, insulin pumps, and insulin syringes. For each segment, the market size is provided in terms of value (USD).
| By Drug | ||||||
| ||||||
| ||||||
| ||||||
| Others |
| By Device | |
| Insulin Pumps | |
| Insulin Pens | |
| Insulin Syringes |
Italy Insulin Drugs And Delivery Devices Market Research FAQs
How big is the Italy Insulin Drugs And Delivery Devices Market?
The Italy Insulin Drugs And Delivery Devices Market size is expected to reach USD 531.86 million in 2024 and grow at a CAGR of 1.5% to reach USD 572.96 million by 2029.
What is the current Italy Insulin Drugs And Delivery Devices Market size?
In 2024, the Italy Insulin Drugs And Delivery Devices Market size is expected to reach USD 531.86 million.
Who are the key players in Italy Insulin Drugs And Delivery Devices Market?
Medtronics, Sanofi, F. Hoffmann-La Roche Ltd, Eli Lilly and Company and Becton, Dickinson and Company are the major companies operating in the Italy Insulin Drugs And Delivery Devices Market.
What years does this Italy Insulin Drugs And Delivery Devices Market cover, and what was the market size in 2023?
In 2023, the Italy Insulin Drugs And Delivery Devices Market size was estimated at USD 523.88 million. The report covers the Italy Insulin Drugs And Delivery Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Italy Insulin Drugs And Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Italy Insulin Drugs And Delivery Devices Industry Report
Statistics for the 2024 Italy Insulin Drugs And Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Italy Insulin Drugs And Delivery Devices analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
